4-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.
Jordan M Estroff, Joseph Devlin, Lara Hoteit, Adnan Hassoune, Matthew D Neal, Joshua B Brown, Liling Lu, Shannon Kotch, Joshua P Hazelton, Ashton B Christian, Eric O Yeates, Jeffry Nahmias, Lewis E Jacobson, Jamie Williams, Kevin M Schuster, Rick O'Connor, Gregory R Semon, Angela D Straughn, Daniel Cullinane, Tanya Egodage, Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani
{"title":"4-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.","authors":"Jordan M Estroff, Joseph Devlin, Lara Hoteit, Adnan Hassoune, Matthew D Neal, Joshua B Brown, Liling Lu, Shannon Kotch, Joshua P Hazelton, Ashton B Christian, Eric O Yeates, Jeffry Nahmias, Lewis E Jacobson, Jamie Williams, Kevin M Schuster, Rick O'Connor, Gregory R Semon, Angela D Straughn, Daniel Cullinane, Tanya Egodage, Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani","doi":"10.1097/ta.0000000000004345","DOIUrl":null,"url":null,"abstract":"Andexanet Alfa (AA) is the only FDA approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with 4-Factor Prothrombin Complex Concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing non-inferiority of PCC.","PeriodicalId":501845,"journal":{"name":"The Journal of Trauma and Acute Care Surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Trauma and Acute Care Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ta.0000000000004345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Andexanet Alfa (AA) is the only FDA approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with 4-Factor Prothrombin Complex Concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing non-inferiority of PCC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
